Novaferon for COVID-19 Treatment Trial (NCTT-005)

NCT04708158 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2022-01-28

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate COVID-19 patients

Conditions

  • Covid19

Interventions

BIOLOGICAL

Novaferon

a novel recombinant antiviral protein drug

BIOLOGICAL

Placebo

Saline

Sponsors & Collaborators

  • Genova Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708158 on ClinicalTrials.gov